Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians.
Abstract
There is a growing body of literature supporting the contribution of genetic variability to the mechanisms responsible for the adverse effects of antipsychotic medications particularly movement disorders and weight gain. Despite the current gap between research studies and the practical tools available to the clinician to identify such risks, it is hoped that in the foreseeable future, pharmacogenetics will become a critical aid to guide the development of personalized therapeutic regimes with fewer adverse effects. We provide a summary of two cases that are examples of using cytochrome P450 pharmacogenetics in an attempt to guide treatment in the context of recent literature concerning the role of pharmacogenetics in the manifestation of adverse effects of antipsychotic therapies. These examples and the review of recent literature on pharmacogenetics of antipsychotic adverse effects illustrate the potential for applying the principles of predictive, preventive, and personalized medicine to the therapy of psychotic disorders.Citation
Neuropsychiatr Dis Treat. 2007 Dec; 3(6):965-973Related articles
- Pharmacogenetics of antipsychotic-induced weight gain.
- Authors: Correll CU, Malhotra AK
- Issue date: 2004 Aug
- Pharmacogenetics of antipsychotics: useful for the clinician?
- Authors: Bondy B, Spellmann I
- Issue date: 2007 Mar
- Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications.
- Authors: Yoshida K, Müller DJ
- Issue date: 2020 Apr
- Pharmacogenetics and outcome with antipsychotic drugs.
- Authors: Pouget JG, Shams TA, Tiwari AK, Müller DJ
- Issue date: 2014 Dec
- Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.
- Authors: Elsheikh SSM, Müller DJ, Pouget JG
- Issue date: 2022